Danish drugmaker Novo Nordisk, the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug Tresiba in Germany on May 1 after seeing signs of a more favourable pricing situation there.

Tresiba was approved in the European Union last year, but despite Germany being Europe's biggest market Novo hesitated to market Tresiba because German authorities have been reluctant to support new and more expensive drugs.

"We've recently observed that Germany has started to reward new innovative drugs," Jakob Riis, executive vice president of Marketing & Medical Affairs in Novo Nordisk, told Reuters.

For more details, go to: http://www.cnbc.com/id/101709538